Molecular basis of JAK2 activation in erythropoietin receptor and pathogenic JAK2 signaling
Janus kinase 2 (JAK2) mediates type I/II cytokine receptor signaling, but JAK2 is also activated by somatic mutations that cause hematological malignancies by mechanisms that are still incompletely understood. Quantitative superresolution microscopy (qSMLM) showed that erythropoietin receptor (EpoR) exists as monomers and dimerizes upon Epo stimulation or through the predominant JAK2 pseudokinase domain mutations (V617F, K539L, and R683S). Crystallographic analysis complemented by kinase activity analysis and atomic-level simulations revealed distinct pseudokinase dimer interfaces and activation mechanisms for the mutants: JAK V617F activity is driven by dimerization, K539L involves both increased receptor dimerization and kinase activity, and R683S prevents autoinhibition and increases catalytic activity and drives JAK2 equilibrium toward activation state through a wild-type dimer interface. Artificial intelligence-guided modeling and simulations revealed that the pseudokinase mutations cause differences in the pathogenic full-length JAK2 dimers, particularly in the FERM-SH2 domains. A detailed molecular understanding of mutation-driven JAK2 hyperactivation may enable novel therapeutic approaches to selectively target pathogenic JAK2 signaling.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Science advances - 10(2024), 10 vom: 08. März, Seite eadl2097 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Abraham, Bobin George [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
11096-26-7 |
|---|
| Anmerkungen: |
Date Completed 11.03.2024 Date Revised 15.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1126/sciadv.adl2097 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369472365 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369472365 | ||
| 003 | DE-627 | ||
| 005 | 20240315233535.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240309s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1126/sciadv.adl2097 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1330.xml |
| 035 | |a (DE-627)NLM369472365 | ||
| 035 | |a (NLM)38457493 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Abraham, Bobin George |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Molecular basis of JAK2 activation in erythropoietin receptor and pathogenic JAK2 signaling |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.03.2024 | ||
| 500 | |a Date Revised 15.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Janus kinase 2 (JAK2) mediates type I/II cytokine receptor signaling, but JAK2 is also activated by somatic mutations that cause hematological malignancies by mechanisms that are still incompletely understood. Quantitative superresolution microscopy (qSMLM) showed that erythropoietin receptor (EpoR) exists as monomers and dimerizes upon Epo stimulation or through the predominant JAK2 pseudokinase domain mutations (V617F, K539L, and R683S). Crystallographic analysis complemented by kinase activity analysis and atomic-level simulations revealed distinct pseudokinase dimer interfaces and activation mechanisms for the mutants: JAK V617F activity is driven by dimerization, K539L involves both increased receptor dimerization and kinase activity, and R683S prevents autoinhibition and increases catalytic activity and drives JAK2 equilibrium toward activation state through a wild-type dimer interface. Artificial intelligence-guided modeling and simulations revealed that the pseudokinase mutations cause differences in the pathogenic full-length JAK2 dimers, particularly in the FERM-SH2 domains. A detailed molecular understanding of mutation-driven JAK2 hyperactivation may enable novel therapeutic approaches to selectively target pathogenic JAK2 signaling | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Erythropoietin |2 NLM | |
| 650 | 7 | |a 11096-26-7 |2 NLM | |
| 650 | 7 | |a Janus Kinase 2 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.2 |2 NLM | |
| 650 | 7 | |a Receptors, Erythropoietin |2 NLM | |
| 650 | 7 | |a JAK2 protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.10.2 |2 NLM | |
| 700 | 1 | |a Haikarainen, Teemu |e verfasserin |4 aut | |
| 700 | 1 | |a Vuorio, Joni |e verfasserin |4 aut | |
| 700 | 1 | |a Girych, Mykhailo |e verfasserin |4 aut | |
| 700 | 1 | |a Virtanen, Anniina T |e verfasserin |4 aut | |
| 700 | 1 | |a Kurttila, Antti |e verfasserin |4 aut | |
| 700 | 1 | |a Karathanasis, Christos |e verfasserin |4 aut | |
| 700 | 1 | |a Heilemann, Mike |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Vivek |e verfasserin |4 aut | |
| 700 | 1 | |a Vattulainen, Ilpo |e verfasserin |4 aut | |
| 700 | 1 | |a Silvennoinen, Olli |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Science advances |d 2015 |g 10(2024), 10 vom: 08. März, Seite eadl2097 |w (DE-627)NLM247717614 |x 2375-2548 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2024 |g number:10 |g day:08 |g month:03 |g pages:eadl2097 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1126/sciadv.adl2097 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2024 |e 10 |b 08 |c 03 |h eadl2097 | ||